Process for producing humanized chimera antibody

Abstract

A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

1 . A human chimeric antibody which binds to ganglioside GD 3 , wherein the antibody recognizes the epitope which is recognized by the human chimeric antibody KM-871 produced by a transformant KM-871 (FERM BP-3512).  
     
     
         2 . The chimeric antibody according to  claim 1 , wherein said the human chimeric antibody KM-871 comprises a heavy chain variable region and a light chain variable region of a non human antibody, and a heavy chain constant region and a light chain constant region of a human antibody, wherein said chimeric antibody binds the ganglioside GD 3  and said non human antibody is a mouse monoclonal antibody KM-641 produced by a transformant KM-641 (FERM BP-3116).  
     
     
         3 . The chimeric antibody according to  claim 2 , wherein said the heavy chain variable region has the amino acid sequence of residues 11 to 129 defined in SEQ ID NO: 18.  
     
     
         4 . The chimeric antibody according to  claim 2 , wherein said the light chain variable region has the amino acid sequence of residues 21 to 127 defined in SEQ ID NO: 19.  
     
     
         5 . The chimeric antibody according to  claim 2 , wherein said the human chimeric antibody KM-871 comprises a heavy chain variable region and a light chairs variabe region of a non human antibody, and a heavy chain constant region and a light chain constant region of a human antibody, wherein said chimeric antibody binds the ganglioside GD 3 , said heavy chain variable region has the amino acid sequence of residues 11 to 129 defined in SEQ ID NO:18; and said light chain variable region has the amino acid sequence of residues 21 to 127 defined in SEQ ID NO: 19.  
     
     
         6 . The human chimeric antibody according to  claim 1 , wherein said antibody binds to ganglioside GD 3  and 3′,8′-LD1.